Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Integrative Insights into Biology, Diagnosis and Treatment of Pulmonary Diseases
share announcement

Integrative Insights into Biology, Diagnosis and Treatment of Pulmonary Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 January 2027 | Viewed by 1369

Editor

Dr. Te-Chun Shen

E-Mail Website
Guest Editor
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan
2. School of Medicine, China Medical University, Taichung, Taiwan
Interests: pulmonary and critical care medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pulmonary medicine is advancing at an unprecedented pace, driven by breakthroughs in disease biology, innovations in diagnostic technologies, and the development of novel therapeutic strategies. Respiratory disorders—including lung cancer, asthma, COPD, pneumonia, ARDS, interstitial lung diseases, and pleural conditions—remain major contributors to global morbidity and mortality. Understanding their underlying mechanisms and improving diagnostic and treatment approaches are crucial for enhancing patient outcomes.

We are pleased to invite you to contribute to this Special Issue, titled “Integrative Insights into Biology, Diagnosis and Treatment of Pulmonary Diseases”. This collection aims to integrate current knowledge across basic science, translational research, and clinical practice, aligning closely with the scope of Biomedicines, which highlights molecular mechanisms, innovative diagnostics, and therapeutic development.

This Special Issue seeks comprehensive and up-to-date research articles and reviews that address the multifaceted challenges of pulmonary diseases. We welcome submissions exploring biological pathways, emerging diagnostic modalities, biomarker discovery, therapeutic interventions, and translational strategies that bridge bench research with clinical care.

Original research articles and review manuscripts are welcome. Research areas may include, but are not limited to, the following topics:

  • asthma
  • chronic obstructive pulmonary disease (COPD)
  • interstitial lung disease
  • lung cancer
  • respiratory infection
  • obstructive sleep apnea (OSA)
  • respiratory failure
  • acute respiratory distress syndrome (ARDS)

We look forward to receiving your valuable contributions.

Dr. Te-Chun Shen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pulmonary medicine
  • critical care
  • asthma
  • chronic obstructive pulmonary disease (COPD)
  • interstitial lung disease
  • lung cancer
  • respiratory infection
  • obstructive sleep apnea (OSA)
  • respiratory failure
  • acute respiratory distress syndrome (ARDS)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 1501 KB  
Article
Antibiotic-Induced Pulmonary Fibrosis: National Database Analysis
by Olga Butranova, Yury Kustov, Anna Abramova, Sergey Zyryanov, Irina Asetskaya, Elizaveta Terekhina and Vitaly Polivanov
Biomedicines 2026, 14(6), 1182; https://doi.org/10.3390/biomedicines14061182 - 22 May 2026
Viewed by 386
Abstract
Background: Pulmonary fibrosis (PF) is a major global health issue associated with substantial morbidity across all age groups. One of the important etiological factors contributing to PF is drug-induced lung injury, which can result from both direct and indirect damage to the [...] Read more.
Background: Pulmonary fibrosis (PF) is a major global health issue associated with substantial morbidity across all age groups. One of the important etiological factors contributing to PF is drug-induced lung injury, which can result from both direct and indirect damage to the pulmonary parenchyma caused by various pharmacological agents, including chemotherapeutics, antirheumatic drugs, cardiovascular medications, and certain antimicrobial agents. The aim of our study was to assess the structure of antibacterials involved in drug-induced PF (DIPF) and analyze signals of DIPF, calculating the reporting odds ratio (ROR) and proportional reporting ratio (PRR) using spontaneous reports (SRs) extracted from the Russian National Pharmacovigilance database. Methods: A retrospective, descriptive pharmacoepidemiological analysis of SRs from the AIS database for the period 1 April 2019–31 March 2025 was conducted. Results: A total of 130 SRs with data on DIPF associated with antibacterial agents were identified, with patients’ mean age of 59.1 ± 14.46 years. Death was reported in 65 SRs (50%) with a mean age of 53.0 ± 13.66 years. Next, antibacterials were identified as leaders: sulfamethoxazole (used alone or in combination with trimethoprim, 20.7% (n = 50)), azithromycin (18.2%, n = 44), levofloxacin (12.4%, n = 30), doxycycline (11.6%, n = 28), and cefuroxime (10.7%, n = 26). Disproportionality analysis performed with PRR and ROR calculation revealed the strongest association with DIPF for cefuroxime (PRR = 15.11, 95% confidence interval, CI: 10.25–22.27; ROR = 15.31, 95% confidence interval, CI: 10.33–22.68). Conclusions: Cefuroxime was revealed as a drug with an unexpected but robust safety signal for DIPF, warranting heightened clinical awareness and further investigation. The observed associations between antibacterial agents and DIPF should be interpreted with caution, as they may reflect protopathic bias (antibiotics prescribed for early symptoms of unrecognized pulmonary fibrosis) or context-dependent biological effects rather than true pro-fibrotic drug properties. Our findings do not establish causality but rather generate safety signals that warrant validation through prospective studies with detailed clinical phenotyping and mechanistic investigations using human cell lines. Full article
(This article belongs to the Special Issue Integrative Insights into Biology, Diagnosis and Treatment of Pulmonary Diseases)
►▼ Show Figures

Figure 1

16 pages, 944 KB  
Article
Early Functional Impairment in Smokers with CT-Detected Emphysema: Spirometry Provides Complementary Physiological Information in Lung Cancer Screening
by Sanja Dimic-Janjic, Ivana Buha, Jelena Cvejic, Nikola Kostadinovic, Slavko Stamenic, Anka Postic, Ana Ratkovic, Kristina Stosic-Markovic, Ivana Sekulovic-Radovanovic, Marija Vukoja, Nikola Trboljevac, Lidija Isovic, Ruza Stevic, Nikola Colic, Katarina Lukic, Spasoje Popevic, Natasa Djurdjevic, Milan Savic, Nikola Subotic and Mihailo Stjepanovic
Biomedicines 2026, 14(4), 847; https://doi.org/10.3390/biomedicines14040847 - 8 Apr 2026
Viewed by 640
Abstract
Background: Low-dose computed tomography (LDCT) lung cancer screening (LCS) frequently identifies emphysema in high-risk smokers. However, the extent to which CT-detected emphysema reflects underlying physiological impairment remains uncertain. We evaluated whether spirometry can detect functional abnormalities in this population beyond structural imaging [...] Read more.
Background: Low-dose computed tomography (LDCT) lung cancer screening (LCS) frequently identifies emphysema in high-risk smokers. However, the extent to which CT-detected emphysema reflects underlying physiological impairment remains uncertain. We evaluated whether spirometry can detect functional abnormalities in this population beyond structural imaging findings. Methods: This cross-sectional study included 323 individuals with LDCT- detected emphysema and no lung cancer or prior chronic respiratory diseases within a screening cohort (n = 3076). Participants underwent pre-bronchodilator spirometry and symptom assessments (COPD Assessment test (CAT) and Modified Medical Research Council (mMRC) Dyspnea Scale). Pre-bronchodilator airflow limitation was defined as forced expiratory volume in one second to forced vital capacity ratio (FEV1/FVC) < 0.70. Small airways dysfunction was defined by ≥2 reduced mid-expiratory flow parameters (<60% predicted). Flow–volume curve morphology was assessed qualitatively. Results: Pre-bronchodilator airflow limitation was observed in 45.2% of participants, predominantly mild. Small-airway dysfunction was present in 52%, and an abnormal flow–volume curve morphology in 67.5%. Notably, functional abnormalities were frequently observed despite preserved FEV1. Symptom burden was low, with only 7.7% of participants reporting clinically significant symptoms. Functional impairments often overlapped and were common in minimally symptomatic individuals. Conclusions: In a lung cancer screening (LCS) cohort with CT-detected emphysema, functional abnormalities are frequently observed, including in individuals with preserved FEV1 and minimal symptoms. Spirometry provides additional physiological insight beyond structural imaging; however, these findings are descriptive and should not be interpreted as diagnostic of COPD. Further studies are needed to determine their clinical relevance. Full article
(This article belongs to the Special Issue Integrative Insights into Biology, Diagnosis and Treatment of Pulmonary Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop